Overview

FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer

Status:
Unknown status

Trial end date:
2015-04-01

Target enrollment:
0

Participant gender:
Male

Summary

To compare intermittent androgen deprivation (LHRHa treatment) with continuous androgen deprivation (LHRHa treatment or orchidectomy)

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Tampere University
University of Tampere

Collaborator:

Finnish Prostate Cancer Group

Treatments:

Androgens
Goserelin

Criteria

• Inclusion Criteria (run-in period): T1-T4, metastatic (M1) prostate cancer T1-T4,
non-metastatic (M0) prostate cancer with PSA > 60 ng/mL T3-T4, non-metastatic (M0) prostate
cancer with PSA > 20ng/mL T1-T4, N+ prostate cancer WHO performance status 0-2 Written
informed consent

• Inclusion criteria to the randomised period: Patients who fulfilled all entry criteria of
the run-in period Patients who completed the 24-week run-in period Patients who responded
to the 24-week run-in period with a decrease of PSA to < 10 ng/mL. If the baseline was <
20ng/mL, at least 50% decrease from the baseline measurement is required

Exclusion Criteria (run-in period):

Any previous or concurrent treatment of prostate cancer, except TURP, 5-alpha reductase
inhibitor, radical prostatectomy or radiotherapy Any medication/treatment affecting sex
hormone status

-